Acrivon Therapeutics, Inc. (NASDAQ:ACRV) disclosed that its President and Chief Executive Officer, Peter Blume-Jensen, sold common stock valued at $2,581 on November 17, 2026. The transaction involved 1,780 shares at a price of $1.45 per share.
The sale was executed to meet mandatory tax withholding requirements triggered by the vesting of restricted stock units. Of the total, Dr. Blume-Jensen directly disposed of 1,276 shares. An additional 504 shares were indirectly disposed of by Dr. Kristina Masson, co-founder and Executive Vice President of Acrivon Therapeutics and Dr. Blume-Jensen's spouse.
The reported price of $1.45 represents the weighted average price of 4,070 shares sold by a broker on the same date to cover withholding tax liabilities for a group of the Issuer's employees, with proceeds allocated pro rata.
The transaction comes as Acrivon's stock trades at $1.40, down 42% year-to-date and near its 52-week low of $1.27. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value of $1.84, making it one to watch on the platform's most undervalued stocks list.
Following these transactions, Dr. Blume-Jensen directly holds 2,228,776 shares of Acrivon Therapeutics common stock. Dr. Masson indirectly holds 385,355 shares. Dr. Masson disclaims beneficial ownership of the directly held securities by Dr. Blume-Jensen except to the extent of her pecuniary interest, and Dr. Blume-Jensen disclaims beneficial ownership of the indirectly held securities by Dr. Masson except to the extent of his pecuniary interest.
The filing was signed by Adam D. Levy, acting as Attorney-in-Fact for both Dr. Blume-Jensen and Dr. Masson, on November 19, 2026.
In other recent news, Jefferies has reiterated its Buy rating for Acrivon Therapeutics, maintaining a price target of $14.00. This decision follows an inflammation and immunology key opinion leader event that provided insights into the company's drug development path. Jefferies expressed increased confidence in Acrivon's management and the rationale for the development of ACR-525. The firm noted that the event and subsequent management discussions have positively influenced their outlook on the company. These recent developments highlight the ongoing advancements in Acrivon's therapeutic projects.
For deeper insights into Acrivon's financial health and future prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro for this and 1,400+ other US equities.